China Approves Lilly Obesity Pill as Market Forecast to Reach 30 Billion Yuan
Key Facts
China has approved Eli Lilly’s weight-loss pill orforglipron, Reuters reported on November 12, 2026, citing China’s drug regulator. The decision marks a regulatory step in Lilly’s favor in a market where drugmakers are racing to develop obesity treatments. It comes as Novo Nordisk’s application to market an oral version of Wegovy remains under review, after the regulator accepted it on August 27, 2026. The approval gives Lilly an early lead among the two oral applications covered in the reports, without settling when the drug will be commercially available. The approval report did not give a price for the drug or a date for the start of sales in China.
The significance of the approval extends beyond the two companies’ progress on pills: Novo, Lilly, Pfizer and China’s Innovent are also competing for a share of the market for weekly GLP-1 weight-loss injections. Orforglipron gives Lilly an oral option taken once daily, according to the company’s description cited by Reuters. The drug is a non-peptide GLP-1 receptor agonist and was tested in adults who were overweight and did not have diabetes. In a late-stage trial, participants on the highest dose lost 12.4% of their body weight over 72 weeks. The trial result provides background on the product, while the published approval details do not include information on the terms under which it will be made available to Chinese consumers.
The competition is underpinned by a market expected to grow as overweight and obesity become more prevalent in China. Reuters cited an estimate from the National Health Commission that the share of the population affected by either condition could exceed 65% by 2030. Yang Huang, head of China healthcare research at JPMorgan, said sales of GLP-1 treatments for weight management could reach 30 billion yuan within five to seven years. That compares with a current estimate of 3 to 4 billion yuan, according to comments cited by Reuters. These estimates cover the treatment market generally and do not specify Lilly’s share or potential sales of its drug following approval.
Lilly’s plans in China are backed by an investment the company said it intends to make over the next decade. It said it plans to invest 3 billion dollars in the country, with the funding helping to build production capacity for orforglipron. This is part of the commercial and industrial path that preceded the approval, while the company’s report did not specify when sales would begin or the price in the Chinese market. In the United States, Lilly said in its third-quarter disclosure that it launched Foundayo for obesity during the second quarter of 2026 and submitted orforglipron to the Food and Drug Administration for the treatment of type 2 diabetes. These steps place the product within the company’s plans outside China as well, without revealing whether Chinese availability will follow the same timetable.
There have previously been indications of the scale of commercial activity for GLP-1 treatments in China: sales of these treatments through Alibaba and JD.com totaled about 1.4 billion yuan in the first quarter of 2026, according to a Jefferies estimate cited by Reuters in June. The figure covers sales through two online platforms and does not represent the entire Chinese market. In the United States, the Associated Press noted the Food and Drug Administration’s approval of orforglipron in April 2026 and said Lilly’s application review took 50 days. The agency reported that participants on the highest dose lost 11.2% of their body weight in a trial involving more than 3,000 adults with obesity. That result differs from the late-stage trial result reported by Reuters, as it concerns a trial and measurement period cited by the agency.
While Chinese approval has now been announced, details on the move to sales remain among the key commercial developments awaited, as Reuters’ report did not specify a price or launch date. Novo’s oral Wegovy application remains under review after China’s regulator accepted it in August. The four companies are also continuing to compete in the weekly injection market, alongside the race for oral treatments. Eli Lilly shares closed at 1437.29 dollars on November 11, 2026, the last session before the approval news. The facts reported here do not include verified data on the share’s movement during the November 12 session.